The Role of Market Incentives in Europe for the Development of New Therapies

Antimicrobial Resistance (AMR) is one of the biggest threats to global health. In the face of rapidly increasing resistance and a nearly exhausted antibiotic pipeline, it is crucial to establish innovative strategies to promote the development of new antimicrobials.Within the European Union, solutions urgently need to be found in collaboration with all relevant stakeholders. While market incentives for new antibiotics are still being discussed in the European Union, the United Kingdom has already implemented a model. Targeted incentives are needed to motivate pharmaceutical companies to invest in the research and development of new antimicrobial agents.Close cooperation between politics, science and industry is essential in order to develop sustainable and forward-looking models. As AMR is a global problem, coordinated action at national, European and international level is essential.